What is a stock summary page? Click here for an overview.
Business Description
BioInvent International AB
ISIN : SE0015244520
Description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 49.8 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 10.88 | |||||
| Beneish M-Score | -2.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.8 | |||||
| 3-Year EBITDA Growth Rate | -12.2 | |||||
| 3-Year EPS without NRI Growth Rate | -11 | |||||
| 3-Year FCF Growth Rate | -7.5 | |||||
| 3-Year Book Growth Rate | -16.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 117.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.12 | |||||
| 9-Day RSI | 51.3 | |||||
| 14-Day RSI | 54.36 | |||||
| 3-1 Month Momentum % | -30.05 | |||||
| 6-1 Month Momentum % | -41.87 | |||||
| 12-1 Month Momentum % | 73.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.91 | |||||
| Quick Ratio | 9.79 | |||||
| Cash Ratio | 9.11 | |||||
| Days Sales Outstanding | 369.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4 | |||||
| Shareholder Yield % | 0.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1054.15 | |||||
| Net Margin % | -960.87 | |||||
| FCF Margin % | -873.88 | |||||
| ROE % | -38.83 | |||||
| ROA % | -35.75 | |||||
| ROIC % | -220.95 | |||||
| 3-Year ROIIC % | 84.24 | |||||
| ROC (Joel Greenblatt) % | -955.02 | |||||
| ROCE % | -42.19 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 3.01 | |||||
| PS Ratio | 43.37 | |||||
| PB Ratio | 2.19 | |||||
| Price-to-Tangible-Book | 2.19 | |||||
| EV-to-EBIT | -2.31 | |||||
| EV-to-Forward-EBIT | -3.3 | |||||
| EV-to-EBITDA | -2.41 | |||||
| EV-to-Forward-EBITDA | -3.3 | |||||
| EV-to-Revenue | 24.35 | |||||
| EV-to-Forward-Revenue | 32.07 | |||||
| EV-to-FCF | -2.79 | |||||
| Price-to-GF-Value | 2.64 | |||||
| Price-to-Median-PS-Value | 3.42 | |||||
| Price-to-Net-Current-Asset-Value | 2.31 | |||||
| Price-to-Net-Cash | 2.54 | |||||
| Earnings Yield (Greenblatt) % | -43.29 | |||||
| FCF Yield % | -20.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioInvent International AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 44.686 | ||
| EPS (TTM) (kr) | -6.53 | ||
| Beta | -0.41 | ||
| 3-Year Sharpe Ratio | 0.12 | ||
| 3-Year Sortino Ratio | 0.2 | ||
| Volatility % | 81.46 | ||
| 14-Day RSI | 54.36 | ||
| 14-Day ATR (kr) | 0.681998 | ||
| 20-Day SMA (kr) | 28.65625 | ||
| 12-1 Month Momentum % | 73.88 | ||
| 52-Week Range (kr) | 15.83 - 49.35 | ||
| Shares Outstanding (Mil) | 65.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioInvent International AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioInvent International AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioInvent International AB Frequently Asked Questions
What is BioInvent International AB(LTS:0H22)'s stock price today?
The current price of LTS:0H22 is kr29.35. The 52 week high of LTS:0H22 is kr49.35 and 52 week low is kr15.83.
When is next earnings date of BioInvent International AB(LTS:0H22)?
The next earnings date of BioInvent International AB(LTS:0H22) is 2025-04-29.
Does BioInvent International AB(LTS:0H22) pay dividends? If so, how much?
BioInvent International AB(LTS:0H22) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers